Dear Customer, If you experience any text readability or display issues on our website, please update your web browser to the latest version
.
See More
Dear Customer, If you experience any text readability or display issues on our website, please update your web browser to the latest version
.
See MoreDear Customer, If you experience any text readability or display issues on our website, please update your web browser to the latest version
.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current location site or be switched to your location?
Expression of TNF by RiCK-2 Positive control cells. In vitro differentiated and re-stimulated LOU lymphocytes (RiCK-2 Cells, Cat. No. 555094) were fixed, permeabilized, and subsequently stained with PE-conjugated rat anti-mouse TNF antibody (PE-TN3-19.12, Cat. No. 559503) by using Pharmingen's staining protocol (see Figure, left panel). To demonstrate specificity of staining, the binding of PE-TN3-19.12 was blocked by the preincubation of the conjugated antibody with molar excess of recombinant rat TNF (0.25 µg, Cat. No. 555109; middle panel), and by preincubation of the fixed/permeabilized cells with an excess of the unlabeled TN3-19.12 mAb (5µg, Cat. No. 557516; right panel). The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking (middle panel) and unlabeled antibody blocking specificity controls.
Expression of TNF by RiCK-2 Positive control cells. In vitro differentiated and re-stimulated LOU lymphocytes (RiCK-2 Cells, Cat. No. 555094) were fixed, permeabilized, and subsequently stained with PE-conjugated rat anti-mouse TNF antibody (PE-TN3-19.12, Cat. No. 559503) by using Pharmingen's staining protocol (see Figure, left panel). To demonstrate specificity of staining, the binding of PE-TN3-19.12 was blocked by the preincubation of the conjugated antibody with molar excess of recombinant rat TNF (0.25 µg, Cat. No. 555109; middle panel), and by preincubation of the fixed/permeabilized cells with an excess of the unlabeled TN3-19.12 mAb (5µg, Cat. No. 557516; right panel). The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking (middle panel) and unlabeled antibody blocking specificity controls.
Expression of TNF by RiCK-2 Positive control cells. In vitro differentiated and re-stimulated LOU lymphocytes (RiCK-2 Cells, Cat. No. 555094) were fixed, permeabilized, and subsequently stained with PE-conjugated rat anti-mouse TNF antibody (PE-TN3-19.12, Cat. No. 559503) by using Pharmingen's staining protocol (see Figure, left panel). To demonstrate specificity of staining, the binding of PE-TN3-19.12 was blocked by the preincubation of the conjugated antibody with molar excess of recombinant rat TNF (0.25 µg, Cat. No. 555109; middle panel), and by preincubation of the fixed/permeabilized cells with an excess of the unlabeled TN3-19.12 mAb (5µg, Cat. No. 557516; right panel). The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking (middle panel) and unlabeled antibody blocking specificity controls.
Expression of TNF by RiCK-2 Positive control cells. In vitro differentiated and re-stimulated LOU lymphocytes (RiCK-2 Cells, Cat. No. 555094) were fixed, permeabilized, and subsequently stained with PE-conjugated rat anti-mouse TNF antibody (PE-TN3-19.12, Cat. No. 559503) by using Pharmingen's staining protocol (see Figure, left panel). To demonstrate specificity of staining, the binding of PE-TN3-19.12 was blocked by the preincubation of the conjugated antibody with molar excess of recombinant rat TNF (0.25 µg, Cat. No. 555109; middle panel), and by preincubation of the fixed/permeabilized cells with an excess of the unlabeled TN3-19.12 mAb (5µg, Cat. No. 557516; right panel). The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking (middle panel) and unlabeled antibody blocking specificity controls.
Expression of TNF by RiCK-2 Positive control cells. In vitro differentiated and re-stimulated LOU lymphocytes (RiCK-2 Cells, Cat. No. 555094) were fixed, permeabilized, and subsequently stained with PE-conjugated rat anti-mouse TNF antibody (PE-TN3-19.12, Cat. No. 559503) by using Pharmingen's staining protocol (see Figure, left panel). To demonstrate specificity of staining, the binding of PE-TN3-19.12 was blocked by the preincubation of the conjugated antibody with molar excess of recombinant rat TNF (0.25 µg, Cat. No. 555109; middle panel), and by preincubation of the fixed/permeabilized cells with an excess of the unlabeled TN3-19.12 mAb (5µg, Cat. No. 557516; right panel). The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking (middle panel) and unlabeled antibody blocking specificity controls.
Expression of TNF by RiCK-2 Positive control cells. In vitro differentiated and re-stimulated LOU lymphocytes (RiCK-2 Cells, Cat. No. 555094) were fixed, permeabilized, and subsequently stained with PE-conjugated rat anti-mouse TNF antibody (PE-TN3-19.12, Cat. No. 559503) by using Pharmingen's staining protocol (see Figure, left panel). To demonstrate specificity of staining, the binding of PE-TN3-19.12 was blocked by the preincubation of the conjugated antibody with molar excess of recombinant rat TNF (0.25 µg, Cat. No. 555109; middle panel), and by preincubation of the fixed/permeabilized cells with an excess of the unlabeled TN3-19.12 mAb (5µg, Cat. No. 557516; right panel). The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking (middle panel) and unlabeled antibody blocking specificity controls.
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
The PE-conjugated TN3-19.12 antibody can be used for multicolor immunofluorescent staining and flow cytometric analyses to identify and enumerate rat TNF-producing cells within mixed cell populations (see Figure). For optimal immunofluorescent staining with flow cytometric analysis, this anti-cytokine antibody should be titrated (≤ 0.5 µg mAb/million cells). For specific methodology, please visit our web site, www.bdbiosciences.com, and go to the protocols section or the chapter on intracellular staining in the Immune Function Handbook.
A useful control for demonstrating specificity of staining is either of the following: 1) pre-block the conjugated TN3-19.12 antibody with a molar excess of ligand prior to staining, or 2) pre-block the fixed/permeabilized cells with unconjugated TN3-19.12 antibody (Cat. No. 557516) prior to staining. The staining technique and blocking controls are described in detail by C. Prussin and D. Metcalfe. A suitable hamster IgG1, λ isotype control for assessing the level of background staining on paraformaldehyde-fixed/saponin-permeabilized mouse and human cells is PE-G235-2356 (Cat. No. 554711); use at comparable concentrations to antibody of interest (e.g., ≤ 0.5 µg mAb/ 1 million cells).
OTHER APPLICATIONS
In vitro neutralization: The NA/LE™ format of the TN3-19.12 antibody (Cat. No. 557370) is useful for neutralization of mouse TNF bioactivity.
IP/WB: The TN3-19.12 antibody has been reported to be useful for immunoprecipitation and Western blot. Please note that this application is not routinely tested at BD Biosciences Pharmingen.
ELISA: The purified TN3-19.12 antibody (Cat. No. 557516) can be used as a capture antibody for a sandwich ELISA that measures TNF protein levels.
The TN3-19.12 antibody reacts with rat and mouse tumor-necrosis factor (TNF) proteins (also known as TNF-α) . Moreover, the TN3-19.12 antibody is reported to crossreact with rabbit TNF, but it does not crossreact with mouse lymphotoxin-α (LT-α, also known as TNF-β) nor with human TNF. The immunogen used to generate the TN3-19.12 hybridoma was E. coli-expressed, purified recombinant mouse TNF protein. This monoclonal antibody has been reported to neutralize the bioactivities of mouse, rat and rabbit TNF.
This antibody is routinely tested by flow cytometric analysis. Other applications were tested at BD Biosciences Pharmingen during antibody development only or reported in the literature.
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.